Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 36Breast Neoplasms 32Rectal Neoplasms 25Esophageal Neoplasms 21Uterine Cervical Neoplasms 20Head and Neck Neoplasms 20Central Nervous System Neoplasms 19Lung Neoplasms 18Prostatic Neoplasms 17Lymphoma 17Esophageal Squamous Cell Carcinoma 17Leukemia 16Glioblastoma 16Squamous Cell Carcinoma of Head and Neck 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Carcinoma, Hepatocellular 12Sarcoma 10Neuroblastoma 10Neoplasms 10Nasopharyngeal Carcinoma 10Brain Neoplasms 10Astrocytoma 10Colorectal Neoplasms 9Pancreatic Neoplasms 7Glioma 7Neoplasm Metastasis 6Nasopharyngeal Neoplasms 6Lymphoma, Non-Hodgkin 6Stomach Neoplasms 5Recurrence 5

Interventions

Thyroidectomy 4Iodine-131 4trametinib 3dabrafenib 3apatinib 3anlotinib 2Surgical Procedures, Operative 2Blood Specimen Collection 2Biopsy, Large-Core Needle 2toripalimab 1tislelizumab 1surufatinib 1regorafenib 1penpulimab 1pembrolizumab 1pazopanib 1palbociclib 1olaparib 1lenvatinib 1famitinib 1camrelizumab 1Ultrasonography 1Thyroxine 1Thyrotropin Alfa 1Sunitinib 1Second Harmonic Generation Microscopy 1Routinely Collected Health Data 1Rosiglitazone 1Robotic Surgical Procedures 1Radiotherapy, Intensity-Modulated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Thyroid Neoplasms × Radiotherapy × Clear all
NCT05659186 2022-12-21

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

West China Hospital

Phase 2 Unknown
20 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡